

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

15th July, 2024

To,

| | |
|--|---|
| The Corporate Relationship Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001. <i>Scrip Code: 539523</i> | National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai 400 051. <i>Scrip Symbol: ALKEM</i> |
|--|---|

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI LODR Regulations”) - Intimation for incorporation of Wholly Owned Subsidiary.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations, we wish to inform you that a Wholly Owned Subsidiary (“WOS”) of the Company in the name of ‘**Alixer Nexgen Therapeutics Limited**’ has been incorporated on 12th July, 2024 in India.

Particulars of the disclosure required under SEBI LODR Regulations read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 have been provided in Annexure – I.

Kindly take the same on your records.

Sincerely,

For **Alkem Laboratories Limited**

Divya Mewani

Vice President – Legal and Deputy Company Secretary


ALKEM LABORATORIES LTD.

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

Annexure – I

| Sr. No. | Particulars | Details |
|---------|--|--|
| a. | Name of target entity, details in brief such as size, turnover etc. | <p>Name of WOS: Alixer Nexgen Therapeutics Limited (“Alixer”)</p> <p>Authorized Share Capital of WOS: Rs. 1,00,00,00,000/- (Rupees One Hundred Crores only) divided into 10,00,00,000 Equity Shares of Rs. 10/- each.</p> <p>Subscribed Capital of WOS: Rs. 20,00,000/- (Rupees Twenty Lakhs only) divided into 2,00,000 Equity Shares of Rs. 10/- each.</p> <p>Turnover: Not Applicable</p> |
| b. | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” | Alixer, being a WOS, is a related party of Alkem Laboratories Limited (“Company”). |
| c. | Industry to which the entity being acquired belongs | Pharmaceuticals |
| d. | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | Alixer has been incorporated to conduct research, studies, innovation work and develop novel medicines and treatments in key therapeutic areas and to establish global collaborations. |
| e. | Brief details of any governmental or regulatory approvals required for the acquisition | Not Applicable |
| f. | Indicative time period for completion of the acquisition | Not Applicable |
| g. | Consideration – whether cash consideration or share swap or any other form and details of the same | Cash |
| h. | Cost of acquisition and/or the price at which the shares are acquired | Subscription of 2,00,000 Equity Shares of Rs. 10/- each amounting to Rs. 20,00,000/-. |
| i. | Percentage of shareholding / control acquired and / or number of shares acquired | 100% |

**ALKEM LABORATORIES LTD.**

Regd. Office : ALKEM HOUSE, Senapati Bapat Marg,
Lower Parel (West), Mumbai - 400 013, Maharashtra, India.

• Phone: +91-22-3982 9999 • Fax: 022-2495 2955
• Email: contact@alkem.com • Website: www.alkemlabs.com
• CIN: L00305MH1973PLC174201

| | | |
|----|--|--|
| j. | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | <p>Brief Background: Alixer is incorporated as a WOS of the Company to conduct research, studies, innovation work and develop novel medicines and treatments in key therapeutic areas and to establish global collaborations.</p> <p>Date of Incorporation: 12th July, 2024*</p> <p>Country: India</p> <p>Last 3 years Turnover: Not Applicable</p> |
|----|--|--|

**Note: The Certificate of Incorporation was received on 12th July, 2024 (after the close of working hours) and the intimation is submitted today, being the first working day after receipt of the certificate.*